Animal models of amyotrophic lateral sclerosis

被引:18
作者
Doble, A [1 ]
Kennel, P [1 ]
机构
[1] Aventis Pharma, F-94403 Vitry Sur Seine, France
来源
AMYOTROPHIC LATERAL SCLEROSIS | 2000年 / 1卷 / 05期
关键词
amyotrophic lateral sclerosis; animal models; transgenic mice; superoxide dismutase; cytoskeleton;
D O I
10.1080/146608200300079545
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Animal models of human disease are important in unravelling the pathophysiology of the condition, for exploring the natural history of disease and for evaluating potential therapies. The development of animal models of human neurodegenerative disease such as ALS is particularly challenging, given the paucity of knowledge of their aetiology and the organizational specificity of the human motor system. Nonetheless, a range of spontaneously occurring, experimentally produced, or genetically engineered models of ALS are now available. Although not always a perfect replica of the ALS disease, these models are shown to be of outstanding importance for investigations of the mechanisms of dysfunction/death of motor neurons in vivo. This is particularly true for the transgenic mouse models expressing superoxide dismutase or cytoskeletal proteins. This approach has provided an unparalleled opportunity for testing of potential pharmacological or gene therapies, and it can be expected that the results of these studies will be translated into the clinical advances of the next years.
引用
收藏
页码:301 / 312
页数:12
相关论文
共 152 条
  • [1] Abe K, 1997, J NEUROSCI RES, V48, P63
  • [2] Deletions of the heavy neurofilament subunit tail in amyotrophic lateral sclerosis
    Al-Chalabi, A
    Andersen, PM
    Nilsson, P
    Chioza, B
    Andersson, JL
    Russ, C
    Shaw, CE
    Powell, JF
    Leigh, PN
    [J]. HUMAN MOLECULAR GENETICS, 1999, 8 (02) : 157 - 164
  • [3] Beneficial effects of lysine acetylsalicylate, a soluble salt of aspirin, on motor performance in a transgenic model of amyotrophic lateral sclerosis
    Barnéoud, P
    Curet, O
    [J]. EXPERIMENTAL NEUROLOGY, 1999, 155 (02) : 243 - 251
  • [4] Quantitative meter assessment in FALS mice: A longitudinal study
    Barneoud, P
    Lolivier, J
    Sanger, DJ
    Scatton, B
    Moser, P
    [J]. NEUROREPORT, 1997, 8 (13) : 2861 - 2865
  • [5] SYNAPTOSOMAL GLUTAMATE UPTAKE DECLINES PROGRESSIVELY IN THE SPINAL-CORD OF A MUTANT MOUSE WITH MOTOR-NEURON DISEASE
    BATTAGLIOLI, G
    MARTIN, DL
    PLUMMER, J
    MESSER, A
    [J]. JOURNAL OF NEUROCHEMISTRY, 1993, 60 (04) : 1567 - 1569
  • [6] Late onset death of motor neurons in mice overexpressing wild-type peripherin
    Beaulieu, JM
    Nguyen, MD
    Julien, JP
    [J]. JOURNAL OF CELL BIOLOGY, 1999, 147 (03) : 531 - 544
  • [7] BIRD MT, 1971, ACTA NEUROPATHOL, V92, P789
  • [8] Bogdanov MB, 1998, J NEUROCHEM, V71, P1321
  • [9] Transgenic mouse models of Alzheimer's disease and amyotrophic lateral sclerosis
    Borchelt, DR
    Wong, PC
    Sisodia, SS
    Price, DL
    [J]. BRAIN PATHOLOGY, 1998, 8 (04) : 735 - 757
  • [10] Onset and progression of motor deficits in motor neuron degeneration (mnd) mice are unaltered by the glycine/NMDA receptor antagonist L-701,324 or the MAO-B inhibitor R(-)-deprenyl
    Boyce, S
    Webb, JK
    Carlson, E
    Rupniak, NMJ
    Hill, RG
    Martin, JE
    [J]. EXPERIMENTAL NEUROLOGY, 1999, 155 (01) : 49 - 58